TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03339583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Description: zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
Study: NCT00678431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol with Glucose, and Malate
Description: Dietary supplement delivered in grape juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid placebo
Study: NCT03704675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: Administered orally
Study: NCT00706953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib; pegylated liposomal doxorubicin
Description: 1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
Study: NCT04021979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition Powder Ensure
Description: Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5L PEG
Description: Low volume PEG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-controlled diet
Description: Self-controlled low residue diet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG
Description: Normal volume of PEG
Study: NCT00522405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: * Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: * Under local anesthesia, the Femoral artery would be punctured~* A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~* Superselective catheterization of the hepatic artery feeding the tumor would be done~* By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~* Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~* The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~* Gelfoam particles would be injected following this for embolization
Study: NCT02738203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal 2% Lidocaine
Description: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Surgical Lubricant Jelly
Description: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
Study: NCT01483547

Intervention type: DEVICE
Intervention: Bispectral Index (BIS Vista, Covidien)
Description: BIS values at LOC, PI, ROC.

Intervention type: DEVICE
Intervention: Bispectral Index (BIS Vista, Covidien)
Description: BIS values at LOC, PI, ROC.
Study: NCT03241927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Day 1 of each 3 week cycle
Study: NCT05870605

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study utilizing historical de-identified patient level data; therefore no intervention is given.
Study: NCT02913053

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-aerobic exercise
Description: Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
Study: NCT02928276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RheumaKit: Prediction of the response to anti-TNFs DMARDs
Study: NCT03056300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
Description: Powered Vascular Stapler used on vessels
Study: NCT00044291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hormone therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endocrine therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Study: NCT03934372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
Study: NCT03356392

Intervention type: OTHER
Intervention: telephone call d90
Description: telephone call on day 90 to assess the primary outcome (mRs d90)
Study: NCT00044291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antiestrogen therapy
Study: NCT04512989

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive assesment using MOCA test
Description: Cognitive assesment using MOCA test
Study: NCT02960412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: 10mg lasix given intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline given intraoperatively as placebo
Study: NCT02932436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 10 mg per os daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
Study: NCT03768193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep serratus anterior plane block
Description: Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgically-placed paravertebral block
Description: Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
Study: NCT01735604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD20-CAR vector-transduced autologous T cells
Description: anti-CD20-CAR vector-transduced autologous T cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetically engineered lymphocyte therapy
Description: genetically engineered lymphocyte therapy
Study: NCT01718483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: 50 or 70 mg administered orally, once-daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once-daily, orally, for up to 12 weeks
Study: NCT03049501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiving condition
Description: The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition condition
Description: The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
Study: NCT00927875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923
Description: Capsule, Oral, starting dose 30 mg, once daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, \& 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
Study: NCT03367000

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ceprolac
Description: The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary counseling (DC)
Description: Received standard dietary counseling at baseline and month 6.
Study: NCT04353726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight management
Description: During a 12-month period, participants will attend a total of 22 diet improvement sessions, each of which will last approximately 1 hour. Twelve sessions will be held in the first 5 months and will be focused on safe and efficient weight loss. The participants will learn to create a personalized weight loss diet from their kitchen based on their diet practice and food preference. The next 10 sessions will be held in the last 7 months and will be focused on weight maintenance and healthy eating. The participants will build skills to select foods and create meals that prevent them from overeating.
Study: NCT00717145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: one risedronate 20 mg DR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 20 mg DR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 35 mg DR tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: One risedronate 35 mg IR tablet
Study: NCT03562078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Quan
Description: the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
Study: NCT02067858

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Study: NCT01959113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Microbiome Transplant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Study: NCT01115452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Potassium nitrate
Description: 5% potassium nitrate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Potassium nitrate
Description: 5% potassium nitrate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5% Potassium nitrate
Description: 2.5% potassium nitrate solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water
Study: NCT03915834

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Mechanical thrombectomy and/or Aspiration
Study: NCT01249911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lreuteri
Description: L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present
Study: NCT02948712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Screening Thermometer
Description: Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NCCN Guidelines: Distress management
Description: Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
Study: NCT03169569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group
Description: For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group
Description: All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
Study: NCT01702467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2647544
Description: Capsules containing 0.5mg to 50mg of GSK2647544.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules.
Study: NCT04606303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab combination with platinum-containing dual-drug chemotherapy.
Description: cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1), or gemcitabine 1250mg/m2 (D1, D8), or Pemetroxel 500mg/m2 (D1)), Toripalimab 240mg D1, Q3W.~If the patient is SD or PD, Toripalimab combined with platinum-containing dual-drug chemotherapy in the third cycle will continue, and a total of 4 cycles can be carried out at most, and the therapeutic effect will be evaluated after each cycle of treatment. If the patient is PR or CR at any time during the treatment (after treatment in the third or fourth cycle), the surgical treatment will be entered. If PR or CR is still not reached after treatment in the fourth cycle, the endpoint of the trial will be reached, theobservation of the patient will be finished, and the subsequent treatment will be decided by the clinician.
Study: NCT04212767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar socket preservation with Platelet-rich fibrin
Description: The sockets of the test group will be filled with two platelet-rich fibrin membranes followed by suture
Study: NCT02432885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: up to 20mg bid
Study: NCT02776839

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile sensing
Study: NCT01283152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)
Description: If randomized to this arm, subjects will receive a 1 time dose of 1 gallon

Intervention type: DRUG
Group type: OTHER
Intervention: Lactulose
Description: If randomized to this arm, subjects will receive 10-30 grams per standard of care
Study: NCT00822653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calf Muscle Pump Stimulation
Description: Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
Study: NCT00673959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drop FID 111421
Description: Lubricant Eye Drop FID 111421 1 drop each eye one time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drop
Description: Optive Lubricant Eye Drop 1 drop each eye one time
Study: NCT03620058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART22-65s cells
Description: Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART22-65s cells
Description: Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: huCART19 Cells
Description: Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
Study: NCT00119574

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collaborative Chronic Illness Model
Study: NCT04406415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Oral nafamostat, 10, 50, 100, or 200 mg administered three times daily for up to 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo administered three times daily for up to 5 days
Study: NCT00937963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palm DAG Oil
Description: Use of Palm DAG Oil to replace palm oil traditionally used in foods
Study: NCT01943487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC905
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil
Description: Oral
Study: NCT00528424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
Study: NCT02770638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoop Stretcher
Description: Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long Back Spinal board
Description: Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
Study: NCT03564990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive, multifaceted approach
Description: A health education module consisting of a lecture and workshop was incorporated into a health-care course.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional approach
Description: conventional follow-up
Study: NCT01513993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring for patients with Congestive Heart Failure
Description: Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms.
Study: NCT04381780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Recovery Factors
Description: A unique porcine serum based polypeptide nutritional support
Study: NCT01582113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.